TISIDB

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Single-pass membrane protein
Domain	PF00168 C2 domain
Function	May be involved in Ca(2+)-dependent exocytosis of secretory vesicles through Ca(2+) and phospholipid binding to the C2 domain or may serve as Ca(2+) sensors in the process of vesicular trafficking and exocytosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001505 regulation of neurotransmitter levels GO:0006836 neurotransmitter transport GO:0006887 exocytosis GO:0006898 receptor-mediated endocytosis GO:0006906 vesicle fusion GO:0007269 neurotransmitter secretion GO:0016050 vesicle organization GO:0016079 synaptic vesicle exocytosis GO:0017156 calcium ion regulated exocytosis GO:0017157 regulation of exocytosis GO:0017158 regulation of calcium ion-dependent exocytosis GO:0023061 signal release GO:0036465 synaptic vesicle recycling GO:0044801 single-organism membrane fusion GO:0045055 regulated exocytosis GO:0046928 regulation of neurotransmitter secretion GO:0048167 regulation of synaptic plasticity GO:0048284 organelle fusion GO:0048488 synaptic vesicle endocytosis GO:0048489 synaptic vesicle transport GO:0048791 calcium ion-regulated exocytosis of neurotransmitter GO:0048792 spontaneous exocytosis of neurotransmitter GO:0050804 modulation of synaptic transmission GO:0050806 positive regulation of synaptic transmission GO:0051588 regulation of neurotransmitter transport GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0060291 long-term synaptic potentiation GO:0060627 regulation of vesicle-mediated transport GO:0061025 membrane fusion GO:0072583 clathrin-dependent endocytosis GO:0090174 organelle membrane fusion GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0099003 vesicle-mediated transport in synapse GO:0099504 synaptic vesicle cycle GO:0099531 presynaptic process involved in chemical synaptic transmission GO:0099643 signal release from synapse GO:1903305 regulation of regulated secretory pathway
Molecular Function	GO:0000149 SNARE binding GO:0005543 phospholipid binding GO:0005544 calcium-dependent phospholipid binding GO:0019905 syntaxin binding GO:0030276 clathrin binding
Cellular Component	GO:0008021 synaptic vesicle GO:0030133 transport vesicle GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030672 synaptic vesicle membrane GO:0070382 exocytic vesicle GO:0098793 presynapse GO:0099501 exocytic vesicle membrane GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-6794361: Interactions of neurexins and neuroligins at synapses R-HSA-112316: Neuronal System R-HSA-6794362: Protein-protein interactions at synapses

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SYT12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SYT12 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SYT12 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.029	0.937
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.009	0.105
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.688	0.198
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.134	0.828
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.119	0.927
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.457	0.782
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.682	0.432
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.867	0.504
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.526	0.706
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.504	0.489
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.143	0.879
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.689	0.0152

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SYT12 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYT12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYT12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYT12. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYT12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SYT12 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SYT12 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SYT12
Name	synaptotagmin XII
Aliases	sytXII; synaptotagmin-XII; Synaptotagmin-12
Chromosomal Location	11q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SYT12 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SYT12